Login to Your Account  Analysis of the Market: Will Hype Become
Reality?  Managing Editor  Amid a fast warm-up and high
expectations the market is a go  The development of the RNAi
biotechnology sector has been generally managing according to
projection on its fundamental levels since its discovery and as
the market segment progresses toward clinical trials that it
envisions will eventually deliver therapeutics to market.  There
have been problems, such as the intellectual property disputes
and uncertainty associated with anticipated entry into clinical
trials, but such issues are projected to be potholes rather than
dead ends.  The confidence of the companies is validated thus
far by promising research, positive investor interest, and
upbeat market forecasts, as well as by the absence of any
negative market indicators. The field is not oversaturated with
companies rushing to practice the technology, therapeutic
companies have focused R&D platforms that concentrate on select
targets rather than diluting goals